Processa Pharmaceuticals, Inc. Share-based Payment Arrangement, Expensed and Capitalized, Amount
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $2.37 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2021-11-12
- Processa Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2021-09-30 was $981.87K.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month |
|---|---|---|---|
| 2021-09-30 | $981.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.37M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.38M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |